Qiansui International Group Co Ltd
Change company Symbol lookup
Select an option...
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
AEG Aegon NV
MGP MGM Growth Properties LLC
WRB W R Berkley Corp
Go


Based in China
Company profile

Qiansui International Group Co Ltd, formerly Ariel Clean Energy Inc, is a shell company. The Company is engaged in seeking new business opportunities with business entities for merger with or acquisition of a target business. The Company may seek a business opportunity with entities that have commenced operations, or entities wishing to utilize the public marketplace in order to raise additional capital to expand business development activities, to develop a new product or service, or for other corporate purposes. The Company may acquire assets and establish subsidiaries in various businesses or acquire existing businesses as subsidiaries. In implementing a structure for a particular business acquisition or opportunity, the Company may become a party to a merger, consolidation, reorganization, joint venture or licensing agreement with another corporation or entity. The Company may also acquire stock or assets of an existing business. The Company does not have a source of revenue.

Closing Price
$1.23
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.23
Day's Low
1.23
Volume
(Heavy Day)
Volume:
550

10-day average volume:
418
550

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors

11:15 am ET May 4, 2021 (PR Newswire) Print

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021, inclusive (the "Class Period"). Acadia investors have until June 18, 2021 to file a lead plaintiff motion.

https://mma.prnewswire.com/media/1221557/The_Law_Offices_of_Frank_R_Cruz_Logo.jpg

If you are a shareholder who suffered a loss, click here to participate.

Acadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder. In June 2020, Acadia submitted a supplemental New Drug Application ("sNDA") with the U.S. Food and Drug Administration ("FDA") to expand pimavanserin's label to include treatment for dementia-related psychosis.

On March 8, 2021, the Company revealed that, as part of its ongoing review of the sNDA, the FDA "has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time."

On this news, Acadia's stock price fell $20.76 per share, or 45.35%, to close at $25.02 per share on March 9, 2021, thereby injuring investors.

On April 5, 2021, pre-market, the Company disclosed receipt of a Complete Response Letter ("CRL") from the FDA indicating that the pimavanserin sNDA could not be approved in its current form. Specifically, the press release stated that the CRL "cited a lack of statistical significance in some of the subgroups of dementia, and insufficient numbers of patients with certain less common dementia subtypes as lack of substantial evidence of effectiveness to support approval."

On this news, Acadia's stock price fell $4.41 per share, or 17.23%, to close at $21.18 per share on April 5, 2021, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (2) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (3) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Acadia securities during the Class Period, you may move the Court no later than June 18, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you purchased Acadia securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

https://c212.net/c/img/favicon.png?sn=LA63288&sd=2021-05-04

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-law-offices-of-frank-r-cruz-announces-the-filing-of-a-securities-class-action-on-behalf-of-acadia-pharmaceuticals-inc-acad-investors-301283461.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

https://rt.prnewswire.com/rt.gif?NewsItemId=LA63288&Transmission_Id=202105041115PR_NEWS_USPR_____LA63288&DateId=20210504

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.